Marengo Therapeutics has won a second FDA Fast Track Designation for invikafusp alfa, its lead T-cell-activating antibody, announced 15 October 2026. Where the drug's first Fast Track designation, granted in January 2025, covered only tumor mutational burden-high (TMB-H) colorectal cancer, the new one covers TMB-H solid tumors of any tissue origin that have progressed after prior therapy — a tissue-agnostic expansion the Cambridge, Massachusetts biotech says is a first for a T-cell agonist in a biomarker-defined population.
Invikafusp alfa's expansion in four numbers
Figures from Marengo's October 2026 announcement and its SITC 2025 and ESMO 2026 disclosures.
From one cancer to any TMB-high tumor
Marengo Therapeutics won its first Fast Track Designation for invikafusp alfa in January 2025, limited to tumor mutational burden-high (TMB-H) metastatic colorectal cancer. The 15 October 2026 designation drops that tissue restriction: it covers unresectable, locally advanced or metastatic solid tumors of any tissue of origin that are TMB-H and have progressed after prior therapy, including checkpoint inhibition. TMB-H status — a count of mutations in a tumor's DNA above a defined threshold — is a biomarker already used to select patients for other immunotherapies, but Marengo says this is the first time an immuno-oncology T-cell agonist has earned Fast Track status in a biomarker-defined, tissue-agnostic population.
The expanded designation draws on data from the company's ongoing Phase 1/2 STARt-001 trial, a global, open-label study of invikafusp alfa as a single agent in advanced, PD-1-resistant solid tumors. The study has reported objective responses across multiple tumor types — including colorectal, gastric, breast, urothelial, endometrial, gastroesophageal, head and neck, and lung cancers — and set a recommended Phase 2 dose of 0.08 mg/kg.
“A second Fast Track Designation, now in a pan-tumor setting, reinforces our conviction that the drug could become a tissue-agnostic immuno-oncology backbone.” Ke Liu, MD, PhD, Chief Development Officer, Marengo Therapeutics — 15 October 2026 announcement
Selective, not broad, T-cell activation
Invikafusp alfa (STAR0602) is built on Marengo's STAR platform — Selective T Cell Activation Repertoire — and is described by the company as a non-clonal TCR activator that delivers an IL-2 signal in a single molecule. Rather than engaging T cells broadly, the way some bispecific T-cell engagers do, it is designed to selectively activate a common Vβ6/Vβ10 T-cell subset, an approach Marengo argues can drive anti-tumor activity with less of the cytokine-release toxicity that has limited other T-cell-activating therapies.
Marengo runs two other platforms alongside STAR: TriSTAR, a trispecific T-cell engager, and MSTAR, a T-cell depletor aimed at autoimmune disease. Invikafusp alfa remains the company's only clinical-stage, wholly owned asset; its two STAR-platform programs partnered with Ipsen in 2022, for up to $1.6 billion in potential milestone payments, are separate, earlier-stage candidates.
Three things the designation leans on
A biomarker, not a tissue
TMB-H status already guides other cancer therapies; using it alone to define the Fast Track population, regardless of where the tumor started, is what Marengo calls a first for a T-cell agonist.
Responses in seven-plus tumor types
The STARt-001 trial has reported objective responses spanning colorectal, gastric, breast, urothelial, endometrial, gastroesophageal, head and neck, and lung cancers, the evidence base cited for the expanded designation.
A molecule built to be selective
Targeting a defined Vβ6/Vβ10 T-cell subset, rather than engaging T cells broadly, is the company's answer to the toxicity that has constrained other T-cell-activating immunotherapies.
A crowded field betting on T-cell engagement
Fast Track designation speeds FDA review and communication during development; it does not indicate a drug works or will eventually be approved, and invikafusp alfa remains investigational with no regulatory approval anywhere. The designation does, however, put Marengo's molecule inside two of oncology's most closely watched categories at once: TMB-H biomarker-selected therapy, where pembrolizumab already carries a tissue-agnostic FDA approval, and T-cell-engaging immunotherapy, a field crowded with bispecific antibodies and CAR-T programs from far larger developers.
What a tissue-agnostic label could be worth
4M+ US cancer diagnoses
Estimated annual US solid-tumor diagnoses that could carry high tumor mutational burden across tumor types, per published TMB-prevalence literature; not a revenue forecast.
Sources: Marengo Therapeutics, Fast Track Designation announcement, 15 October 2026
Regulatory News outlook
We think a tissue-agnostic TMB-H label would be commercially meaningful mainly as a late-line option behind already-approved checkpoint inhibitors, not as a first-line replacement for them, given invikafusp alfa remains in Phase 1/2 with no randomized data yet disclosed.
How we got here: This is a qualitative read, not a market-size estimate: Marengo has not published a commercial forecast, and the TMB-H share of each tumor type cited above comes from the company's own announcement rather than an independent market-research publisher, so we are not treating it as a sized opportunity the way we would a published market report.
Where invikafusp alfa sits among T-cell-activating drugs
| Product | Mechanism | Patient selection | Stage | Latest regulatory action |
|---|---|---|---|---|
| Invikafusp alfa (Marengo) | Selective Vβ6/Vβ10 T-cell agonist, single molecule | TMB-H, any tissue of origin | Phase 1/2 (STARt-001) | 2nd FDA Fast Track designation, Oct 2026 |
| Pembrolizumab (Merck) | PD-1 checkpoint inhibitor | TMB-H, tissue-agnostic (approved indication) | Marketed | FDA tissue-agnostic approval, 2020 |
| Tebentafusp (Immunocore) | Bispecific TCR-CD3 T-cell engager | HLA-A*02:01-positive uveal melanoma | Marketed | FDA approval, 2022 |
From each company's own labelling and announcements; not a clinical comparison. Invikafusp alfa is investigational and not approved.
From an $80 million launch to a second Fast Track
Marengo's path to a tissue-agnostic designation
- 2021
Marengo Therapeutics founded
Launched with $80 million in financing from ATP; Zhen Su, MD, formerly of Merck KGaA's oncology division, became CEO.
- 2022
Ipsen partnership
Ipsen agreed to a $45 million upfront payment and up to $1.6 billion in potential milestones for two earlier-stage STAR-platform candidates, not invikafusp alfa.
- 8 January 2025
First Fast Track designation
FDA grants Fast Track status to invikafusp alfa for TMB-H metastatic colorectal cancer.
- SITC 2025
Pan-tumor activity reported
Marengo discloses single-agent objective responses across seven major solid-tumor indications in the STARt-001 trial.
- 15 October 2026
Second Fast Track designation
FDA expands Fast Track status to any TMB-H solid tumor that has progressed after prior therapy, including checkpoint inhibition.
- 23 October 2026
ESMO 2026 oral presentation
Updated Phase 2 STARt-001 data are scheduled for presentation at the European Society for Medical Oncology Congress in Madrid.
What the designation doesn't settle
A Fast Track designation is a development and review process, not a verdict on efficacy. Marengo has not disclosed randomized trial data against an active comparator, and invikafusp alfa's objective-response figures to date come from an open-label, single-arm trial design, which cannot isolate the drug's effect from patient-selection or other biases the way a randomized study can. The company has also not said when it expects to begin a registrational trial.
- Next data: an oral presentation of updated Phase 2 STARt-001 results at ESMO 2026, 23 October 2026.
- Combination trial: STARt-002 (NCT06827613), a Phase 1b/2 study pairing invikafusp alfa with Gilead's Trodelvy (sacituzumab govitecan) in metastatic breast cancer.
- Not yet disclosed: a registrational trial design or timeline for invikafusp alfa in the newly expanded tissue-agnostic population.
- Separate from this news: Marengo's Ipsen-partnered STAR0501/IPN01203 program, still in Phase 1, which does not carry today's Fast Track designation.
Sources & further reading
- Marengo Therapeutics, “Marengo Therapeutics Receives Second U.S. FDA Fast Track Designation for Invikafusp Alfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-High Solid Tumors That Progress After Prior Therapy, Including Checkpoint Inhibition,” press release, 15 October 2026. prnewswire.com
- OncLive, “Invikafusp Alfa Earns Expanded Fast Track Designation in TMB-H Solid Tumors,” 15 October 2026. onclive.com
- BioPharm International, “FDA Grants Marengo's Invikafusp Alfa Second Fast Track Designation in TMB-H Solid Tumors,” 15 October 2026. biopharminternational.com
- TargetedOnc, “FDA Grants Fast Track Designation to Invikafusp Alfa in TMB-H Colorectal Cancer,” 8 January 2025. targetedonc.com
- ClinicalTrials.gov, “A Study of Invikafusp Alfa (STAR0602) in Participants With Advanced Solid Tumors (STARt-001),” NCT05592626. clinicaltrials.gov
- ClinicalTrials.gov, “A Study of Invikafusp Alfa in Combination With Sacituzumab Govitecan (STARt-002),” NCT06827613. clinicaltrials.gov
- BioSpace, Ipsen and Marengo Therapeutics strategic partnership announcement, 2022. biospace.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did the FDA grant Marengo this time?
A second Fast Track Designation for invikafusp alfa (STAR0602), announced 15 October 2026, covering unresectable, locally advanced or metastatic tumor mutational burden-high (TMB-H) solid tumors of any tissue origin that have progressed after prior therapy, including checkpoint inhibition.
What was the first Fast Track designation for?
FDA granted invikafusp alfa Fast Track status for TMB-H metastatic colorectal cancer specifically, announced 8 January 2025. The new designation broadens that to any solid tumor with the same biomarker.
Is invikafusp alfa approved for any use?
No. It remains investigational. Fast Track designation speeds FDA review and communication during development; it does not indicate the drug works or will be approved.
Is this related to Marengo's Ipsen partnership?
No. Ipsen's 2022 deal with Marengo, worth up to $1.6 billion in potential milestones, covers two other, earlier-stage STAR-platform candidates. Invikafusp alfa is not part of that partnership.
